• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    CyPath Lung Study Backs Assessment, Prompts Imaging, Defers

    PHARMIWEB

    Cleveland Clinic to Feature CyPath Lung in April

    PHARMIWEB

    bioAffinity CyPath Lung Test Sales Surge 146% YoY in Q1 2026

    PHARMIWEB

    Bioaffinity Tech Hosts Virtual Roundtable On Integrating Cypath

    PHARMIWEB

    BioAffinity`s CyPath Lung Helps Skip Biopsies

    BUSSINESSWIRE

    BioAffinity Technologies Reports Record 2025 Revenue & Sales

    PHARMIWEB

    BioAffinity Technologies Launches Extensive Longitudinal Study

    PHARMIWEB

    Bioaffinity Tech Reveals Positive Results For Asthma Therapy

    BUSINESSWIRE

    bioAffinity Expands CyPath Lung Test Validation

    PHARMIWEB

    Bioaffinity Technologies` Cypath Lung Reduces Lung Cancer

    BUSINESSWIRE

    Case Study: CyPath Lung Test`s Clinical Utility

    BUSINESSWIRE

    Bioaffinity Tech Adds Lung Cancer Experts To Advisory Board

    PHARMIWEB

    BioAffinity Lab Maintains CAP Accreditation

    PHARMIWEB

    BioAffinity Spotlights CyPath Lung Test at ACS Roundtable

    PHARMIWEB

    Bioaffinity Technologies Releases Q3 2025 Financial Report

    BUSINESSWIRE

    Bioaffinity Technologies Sees Rising Cypath Lung Test Volume

    BUSINESSWIRE

    bioAffinity Gets Australian Patent for Disease Detection Tech

    BUSINESSWIRE

    Bioaffinity Technologies Showcases Cypath® Lung Processing Method

    PHARMIWEB

    bioAffinity Gets US Patent Allowance for Lung Cancer Test

    PHARMIWEB

    bioAffinity Regains Compliance with Nasdaq Listing Requirements

    PHARMIWEB

    Wallachbeth Capital Closes $1.8M Bioaffinity Tech Stock Financing

    PR NEWSWIRE

    Bioaffinity Technologies Closes $1.8M Direct Stock Financing

    BUSINESSWIRE

    Bioaffinity Technologies Announces $1.8M Common Stock Financing

    PHARMIWEB

    Bioaffinity Technologies Sees Surge In Cypath® Lung Test Volume

    PHARMIWEB

    Bioaffinity Technologies Closes $4.8M Public Offering

    BUSINESSWIRE

    WallachBeth Prices bioAffinity Public Offering at $4.8M

    PR NEWSWIRE

    Bioaffinity Technologies Prices $4.8m Public Offering

    BUSINESSWIRE

    BioAffinity Expands Case Studies Showing Value Of CyPath Lung

    BUSINESSWIRE

    BioAffinity Tech Implements 1-for-30 Stock Split on Sep 19, 2025

    PHARMAWEB

    CyPath Lung Identifies Cancer in Hard-to-Diagnose Pulmonary Case

    PHARMAWEB

    CyPath Lung Tool Improves Lung Cancer Detection in Veterans

    BUSINESSWIRE

    bioAffinity Appoints New Members to Board of Directors

    BUSINESSWIRE

    bioAffinity Closes $1.2M Private Placement, Warrant Deal

    BUSINESSWIRE

    bioAffinity Technologies Reports Second Quarter 2025 Results

    BUSINESSWIRE

    BioAffinity Sets $1.2M Private Placement and Warrant Deal

    BUSINESSWIRE

    BioAffinity Reports Growth Surge in CyPath® Lung Test Sales

    BUSINESSWIRE

    CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Tools

    BUSINESSWIRE

    Canada Grants Patent to bioAffinity for Lung Cancer Test

    BUSINESSWIRE

    bioAffinity Wins China Patent for Lung Cancer Test

    BUSINESSWIRE

    bioAffinity Presents Cancer Research at RNA Conference

    BUSINESSWIRE

    bioAffinity Gets China Patent for siRNA-Based Cancer Therapy

    BUSINESSWIRE

    bioAffinity Technologies CEO Maria Zannes Joins Lung Association

    BUSINESSWIRE

    bioAffinity Technologies Partners with Cardinal Health for CyPath

    BUSINESSWIRE

    bioAffinity Wins US Patent for Broad Cancer Therapeutics

    BUSINESSWIRE

    bioAffinity Technologies Appoints Dr. Gordon Downie as CMO

    BUSINESSWIRE

    bioAffinity Technologies Reports First Quarter 2025 Results

    BUSINESSWIRE

    bioAffinity Technologies Closes $3.25M Offering

    BUSINESSWIRE

    bioAffinity Technologies Prices $3.25M Offering

    BUSINESSWIRE

    bioAffinity Technologies boosts CyPath® Lung Test efficiency by 50%

    BUSINESSWIRE

    bioAffinity Technologies Reports $9.4M Revenue in 2024

    BUSINESSWIRE

    bioAffinity Plans $4M Cost Cuts, Focuses On CyPath® Lung Growth

    BUSINESSWIRE

    bioAffinity Closes $1.4M Warrant Inducement Transaction

    BUSINESSWIRE

    bioAffinity Raises $1.4M Through Warrant Inducement

    BUSINESSWIRE

    bioAffinity Accepts Patent Application for Lung Cancer Diagnostic

    BUSINESSWIRE

    bioAffinity Positive Results From Texas Beta Launch of CyPath Lung

    BUSINESSWIRE

    Join bioAffinity Technologies’ Exclusive Live Investor Webinar

    BUSINESSWIRE

    bioAffinity Technologies Set for Continued Expansion in 2025

    BUSINESSWIRE

    bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

    BUSINESSWIRE

    bioAffinity Technologies Awarded Japanese Patent for CyPath® Lung

    BUSINESSWIRE

    bioAffinity Technologies Closes $2.6 Million Direct Offering

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.